Q4 Earnings Estimate for GT Biopharma Issued By Roth Capital

GT Biopharma, Inc. (NASDAQ:GTBP) – Stock analysts at Roth Capital issued their Q4 2024 earnings estimates for GT Biopharma in a research report issued to clients and investors on Monday, December 2nd. Roth Capital analyst J. Aschoff anticipates that the company will earn ($1.55) per share for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. Roth Capital also issued estimates for GT Biopharma’s Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.47) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($1.21) EPS.

Separately, Roth Mkm started coverage on shares of GT Biopharma in a research report on Monday. They set a “buy” rating and a $11.00 price objective for the company.

GT Biopharma Stock Down 0.4 %

GT Biopharma stock opened at $2.79 on Tuesday. The company has a fifty day simple moving average of $2.66 and a 200 day simple moving average of $2.74. GT Biopharma has a 1-year low of $1.92 and a 1-year high of $10.66.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.